CellCarta and Imagene AI expanded their collaboration to move AI pathology tools into companion diagnostic (CDx) development for non-small cell lung cancer. The partnership focuses on analytical validation, global clinical deployment, and regulatory strategy to help sponsors translate image-analysis and biomarker algorithms into submission-ready assays. The report describes programs covering immunohistochemistry (IHC) quantification and H&E-based prediction, including a Lung Prediction Panel application in NSCLC. Executives positioned the effort as a “single-partner model” designed to handle not only model building but also validation and the logistical bridge from algorithm to clinic. For CDx developers, the update highlights how AI pathology is increasingly treated as an end-to-end regulatory project rather than a standalone technology piece.